What will the effect of these projects be on the medical product development process? How will the Critical Path Initiative help bring new treatments to patients?
These projects will create new, scientific tools that can better evaluate which investigational products do not hold promise, either because they are likely to be too toxic or ineffective, and do so earlier in the development process. With this information, product sponsors can redirect resources to more promising products. Early failures are more efficient failures – they free up resources to be invested in product candidates more likely to successfully get to market. New Critical Path tools will help product sponsors devote those resources to new and better candidates, thus facilitating the availability of more new medical products for patients. In addition, Critical Path calls for incorporation of new scientific approaches—such as genomics, proteomics and advanced imaging technologies—that will lead to more personalized, targeted therapies and preventives that are designed to be safer, more effective and of high quality.
Related Questions
- What will the effect of these projects be on the medical product development process? How will the Critical Path Initiative help bring new treatments to patients?
- I have some ideas for modernizing medical product development, how can I get involved in FDAs Critical Path Initiative?
- What is the Sentinel Initiative?
